Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial

Trial Profile

Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Temozolomide (Primary)
  • Indications Astrocytoma; Glioma; Oligodendroglioma
  • Focus Therapeutic Use
  • Acronyms TAVAREC
  • Most Recent Events

    • 19 Jun 2023 Results assessing the impact of the addition of BEV to TMZ on Health-related quality of life published in the European Journal of Cancer
    • 16 Mar 2022 Results assessing prognostic significance of DNA methylation profiles at MRI enhancing tumor recurrence published in the Clinical Cancer Research
    • 13 Aug 2018 Results published in the Lancet Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top